Stockscreener 앱 받기
2.53
1.17%
-0.03
시장 영업 전:
2.55
0.02
+0.79%
전일 마감가:
$2.56
열려 있는:
$2.57
하루 거래량:
2.25M
Relative Volume:
0.92
시가총액:
$246.98M
수익:
$32.31M
순이익/손실:
$-237.09M
주가수익비율:
-0.8785
EPS:
-2.88
순현금흐름:
$-219.11M
1주 성능:
+4.55%
1개월 성능:
-6.30%
6개월 성능:
+16.06%
1년 성능:
+33.86%
1일 변동 폭
$2.465
$2.60
1주일 범위
$2.36
$2.70
52주 변동 폭
$0.9101
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
명칭
Editas Medicine Inc
전화
617-401-9000
주소
11 HURLEY ST., CAMBRIDGE, MA
EDIT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.53 | 249.90M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-28 | 개시 | H.C. Wainwright | Buy |
| 2024-12-16 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-13 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-11-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-04 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-05-09 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-10-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | 업그레이드 | Stifel | Hold → Buy |
| 2023-06-12 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-13 | 개시 | Citigroup | Neutral |
| 2022-12-06 | 재개 | Credit Suisse | Neutral |
| 2022-11-18 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-09-29 | 개시 | BofA Securities | Neutral |
| 2021-10-19 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-24 | 개시 | Stifel | Hold |
| 2021-09-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-08-09 | 업그레이드 | Truist | Hold → Buy |
| 2021-08-05 | 업그레이드 | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | 개시 | Goldman | Sell |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-26 | 다운그레이드 | Truist | Buy → Hold |
| 2021-01-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | 개시 | Robert W. Baird | Underperform |
| 2020-06-18 | 재개 | SunTrust | Buy |
| 2020-02-21 | 개시 | Wells Fargo | Equal Weight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-10 | 개시 | Guggenheim | Neutral |
| 2018-09-21 | 개시 | Raymond James | Outperform |
| 2018-05-15 | 재확인 | Chardan Capital Markets | Buy |
| 2018-02-13 | 개시 | CLSA | Underperform |
| 2018-01-23 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-07-14 | 개시 | SunTrust | Hold |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-06-02 | 개시 | Jefferies | Hold |
| 2016-02-29 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-29 | 개시 | JP Morgan | Neutral |
| 2016-02-29 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Editas Medicine Inc 주식(EDIT)의 최신 뉴스
What analysts say about Editas Medicine Inc stockTechnology Stock Trends & Small Budget Trading Plans - earlytimes.in
Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? - sharewise.com
Cell & Gene Therapy Market to Reach USD 105.83 Billion by 2033 - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Editas Medicine (EDIT) Price Target Increased by 22.78% to 4.95 - Nasdaq
Editas Medicine (EDIT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Editas Medicine (NASDAQ:EDIT) CEO Sells $12,046.45 in Stock - MarketBeat
Trend Recap: Is Editas Medicine Inc. (8EM) stock supported by free cash flowJuly 2025 Patterns & High Accuracy Swing Trade Signals - moha.gov.vn
What valuation ratios show for Editas Medicine Inc. (8EM) stockEarnings Summary Report & Reliable Intraday Trade Alerts - Newser
CEO O'Neill Surrenders 5,603 Of Editas Medicine Inc [EDIT] - TradingView
Editas Medicine CEO Sells Shares to Meet Tax Obligations - TradingView
How Editas Medicine Inc. (8EM) stock performs in easing cyclesJuly 2025 Selloffs & Safe Entry Momentum Tips - Newser
Editas Medicine (NASDAQ:EDIT) Shares Cross Below 50-Day Moving AverageTime to Sell? - MarketBeat
Will Editas Medicine Inc. (8EM) stock beat Nasdaq index returns2025 Pullback Review & Free Verified High Yield Trade Plans - Newser
Is Editas Medicine Inc. (8EM) stock positioned for digital growth eraMarket Growth Summary & Free Fast Gain Swing Trade Alerts - Newser
CEO O'Neill Files To Sell 7,000 Of Editas Medicine Inc [EDIT] - TradingView
Euro India Fresh Foods Limited Forms Bullish Flag Upside AheadCovered Call Writing & Learn From the Strategies of Institutions - earlytimes.in
FY2025 EPS Estimates for Editas Medicine Lowered by Analyst - MarketBeat
Editas Medicine (NASDAQ:EDIT) Stock Crosses Below 50-Day Moving AverageTime to Sell? - MarketBeat
Portfolio Shifts: Is Editas Medicine Inc. stock a bargain at current levelsMarket Activity Recap & Fast Moving Stock Trade Plans - moha.gov.vn
Can Editas Medicine Inc. stock surprise with earnings upsideTrade Signal Summary & Fast Gain Stock Tips - moha.gov.vn
Editas Medicine Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Access Free Risk Analysis Before You Invest - earlytimes.in
Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates - MSN
Editas Medicine price target raised to $4.60 from $4 at Clear Street - MSN
Is Editas Medicine Inc. (8EM) stock overpriced at current multiplesPortfolio Risk Report & Risk Controlled Swing Trade Alerts - newser.com
Is Editas Medicine Inc. (8EM) stock in buy zone after pullbackJuly 2025 Rallies & AI Powered Market Entry Strategies - newser.com
Will Editas Medicine Inc. (8EM) stock gain from green policies2025 Big Picture & Technical Confirmation Alerts - newser.com
Will Editas Medicine Inc. stock continue upward momentumForecast Cut & Free Technical Pattern Based Buy Signals - newser.com
How Editas Medicine Inc. (8EM) stock responds to job market shiftsJuly 2025 Snapshot & AI Enhanced Market Trend Forecasts - newser.com
Can Editas Medicine Inc. stock sustain market leadershipQuarterly Risk Review & Weekly Chart Analysis and Trade Guides - newser.com
Is Editas Medicine Inc. (8EM) stock expanding market penetrationFed Meeting & High Accuracy Swing Entry Alerts - newser.com
Does Editas Medicine Inc. (8EM) stock trade below intrinsic valueQuarterly Performance Summary & Verified Chart Pattern Trade Signals - newser.com
Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report? - MSN
Is Editas Medicine Inc. stock a smart buy before Fed meetingWeekly Trading Summary & Stock Portfolio Risk Management - newser.com
Should you hold or exit Editas Medicine Inc. nowPortfolio Risk Summary & Verified Short-Term Trading Plans - newser.com
Editas Medicine Inc (EDIT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):